Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Yap

Showing results (131-140 of 260) with videos related to

Pageof 26
Sort By:
Radiation Research|August 8, 2022
Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and ProtonsScott J Bright, David B Flint, David K J Martinus, et al.
Drug Discovery Today|December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2025
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or LymphomasJason J Luke, Randy F Sweis, J Randolph Hecht, et al.
Journal of Gastrointestinal Cancer|April 29, 2023
Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical TrialsRishi Surana, Graciela Nogueras Gonzalez, Jane Rogers, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2010
A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attritionAndre T Brunetto, Joo Ern Ang, David Olmos, et al.
Journal for Immunotherapy of Cancer|November 18, 2025
Prognosis and treatment response stratification according to loss of proofreading (LOP) <i>POLE</i> variantsGiulia Maddalena, Fadl A Zeineddine, Saikat Chowdhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trialsDavid Olmos, Richard D Baird, Timothy A Yap, et al.
Scientific Reports|December 17, 2020
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancerReham Abdel-Wahab, Timothy A Yap, Russell Madison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumorsPaul Haluska, Heather M Shaw, Gretchen N Batzel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2023
Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor CamonsertibEzra Rosen, Timothy A Yap, Elizabeth K Lee, et al.
Pageof 26

Showing results (131-140 of 260) with videos related to

Sort By:
Pageof 26
Radiation Research|August 8, 2022
Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and ProtonsScott J Bright, David B Flint, David K J Martinus, et al.
Drug Discovery Today|December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2025
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or LymphomasJason J Luke, Randy F Sweis, J Randolph Hecht, et al.
Journal of Gastrointestinal Cancer|April 29, 2023
Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical TrialsRishi Surana, Graciela Nogueras Gonzalez, Jane Rogers, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2010
A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attritionAndre T Brunetto, Joo Ern Ang, David Olmos, et al.
Journal for Immunotherapy of Cancer|November 18, 2025
Prognosis and treatment response stratification according to loss of proofreading (LOP) <i>POLE</i> variantsGiulia Maddalena, Fadl A Zeineddine, Saikat Chowdhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trialsDavid Olmos, Richard D Baird, Timothy A Yap, et al.
Scientific Reports|December 17, 2020
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancerReham Abdel-Wahab, Timothy A Yap, Russell Madison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumorsPaul Haluska, Heather M Shaw, Gretchen N Batzel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2023
Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor CamonsertibEzra Rosen, Timothy A Yap, Elizabeth K Lee, et al.
Pageof 26